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primary cancer nests of metastatic patients were infiltrated 
more by intraepithelial (IE) CD56+ cells than were those 
of the non-metastatic patients (p = 0.05). The median OS 
was 41.16 months (range 1.7–98.43). High IE GrB+ infil-
trates predicted longer OS among patients without metasta-
ses (p = 0.028). High IE CD56+ infiltrates were correlated 
with longer OS in metastatic cases (p = 0.009).
Conclusion The combined cytotoxicity of innate and 
adaptive immune effectors infiltrating cancer nests (IE 
GrB+) predicts an improved clinical outcome among non-
metastatic vSCC patients. The functional status of prognos-
tic IE CD56+ infiltrates in immune escaped (metastatic) 
tumors requires further investigation.
Keywords Vulvar cancer · vSCC · CD56+ ·  
Granzyme B · Prognosis · TILs
Introduction
Vulvar cancer has an incidence of 1–2 per 100,000 women 
per year and represents 3–5 % of all gynecological malig-
nancies [1–3]. Squamous cell carcinoma (SCC) is the pre-
dominant malignancy at this site, accounting for approxi-
mately 85–90 % of vulvar cancers [4, 5].
Treatment of advanced stage (FIGO III and IV) vulvar 
cancer patients may be ineffective, even with chemother-
apy and radiotherapy [6, 7]. Therefore, new approaches are 
required including immunotherapy and greater knowledge 
of the factors influencing prognosis.
Tumor infiltrating lymphocytes (TILs) are considered 
to be a manifestation of the host immune response against 
cancer cells [8]. CD8 + lymphocytes represent an important 
subpopulation of cytotoxic T lymphocytes and are the most 
likely effector TILs of adaptive anti-tumor immunity [9].
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Innate anti-tumor immunity is mediated by cells or 
soluble factors that naturally exist in the tumor microenvi-
ronment. Among hematopoietic cells, natural killer (NK) 
(CD3−CD56+) and NK/T (CD3+CD56+) cells have the 
natural ability to eliminate tumor-cell targets [10, 11].
The cytotoxic function of all immune cells critically 
depends on serine proteases known as granzymes. As gran-
zyme B is one of the most abundant granzymes, granzyme 
B-mediated cytotoxicity has been intensively studied [12, 13].
GrB-induced cell death has traditionally been viewed 
as a primary mechanism that is used by adaptive (CD8+) 
as well as innate (NK/NKT) effectors to eliminate harmful 
target cells including tumor cells [12].
Recently, the status of adaptive immunity represented 
by CD8+, CD4+ and FOXP3+ T cells was found to lack 
prognostic significance in vSCC [14–16]. Therefore, the 
purpose of this study was to clarify the prognostic roles of 
innate immune effectors represented by CD56+ cells and 
granzyme B-dependent cytolysis.
Materials and methods
This retrospective study was approved by the Polish Min-
istry of Science and Higher Education review board. The 
board determined that further informed consent was not 
required, as all patients provided informed consent for tis-
sue sampling prior to surgical treatment, including written 
consent for the storage of their information in the hospital 
database and the use of their information for research.
Patients and specimens
This study included 76 patients with verified histopathological 
data and full clinical histories. The clinico-pathological char-
acteristics of this group were carefully described in our two 
previous manuscripts (section: materials and methods) ana-
lyzing the expression of indoleamine 2,3-dioxygenase (IDO) 
and the infiltration of CD8+, CD4+ and FOXP3+ T lympho-
cytes in vSCC [14, 15]. The median age of the patients was 
69.5 years (range 36–85), the median duration of follow-up 
was 51.23 months (range 6.33–135.5), and the median overall 
survival was 41.16 months (range 1.7–98.43) [14, 15].
The immunohistochemical staining and histological 
analyses were performed on paraffin-embedded material 
consisting of 76 primary tumors and additional lymph node 
metastases from 35 patients.
Antibodies
A mouse anti-human monoclonal antibody against CD56 
(cat. No NCL-CD56-1B; concentration 1:400) and a mouse 
anti-human polyclonal antibody against Granzyme B (cat. 
No 760-4283; ready to use) were obtained from Ventana 
Medical Systems, Inc.
Immunohistochemistry
The immunohistochemical staining for CD56 and GrB was 
performed according to the following protocol. Serial sec-
tions with a thickness of 4 μm were cut, deparaffinized and 
subjected to a heat-induced epitope retrieval step before incu-
bation with the primary antibodies. Sections were immersed 
in target retrieval solution (pH 6.0 for CD56, Dako Cytoma-
tion, Denmark) and heated in a pressure cooker. The slides 
were incubated for 90 min with the primary antibodies.
The reaction was visualized by the Novolink Polymer 
Detection System (Novocastra Laboratories). Appropri-
ate positive (normal CD56 and GrB status) and negative 
controls (the primary antibody was replaced with normal 
mouse IgG at an appropriate dilution) were included for 
each case. The immunohistochemical results were evalu-
ated by two independent pathologists who did not have 
access to the clinical data.
Evaluation and classification of CD56+ and GrB+ cells
The degree of immune cell infiltration was determined for 
more than 10 high-power (×400) microscopic fields for 
each tissue sample. Then, five areas with the densest lym-
phocyte distribution (hot spots) were selected and micro-
photographs were taken. The quantitative analysis was 
performed with Multiscan 14.2 software. The numbers of 
CD56+ and GrB+ cells were counted exclusively within 
the primary tumor cancer cell nest. For each case, the mean 
index of CD56+ and GrB+ cells per single high-power 
field was counted and then statistically analyzed.
Patients were divided into CD56 low- and high-intensity 
groups (low CD56+ and high CD56+, respectively) and 
GrB low- and high-intensity groups (low GrB+ and high 
GrB+, respectively) based on median cell number (cut-off 
point) to determine differences in overall survival among 
these groups [12, 14, 15, 17–19].
Statistical analysis
The statistical analysis was performed using the chi-square 
test or Fisher’s exact probability test, followed by the 
Kruskal–Wallis test. Correlations and differences between 
variables were assessed using the Spearman’s rank correla-
tion coefficient.
Overall survival curves were estimated by the Kaplan–
Meier method and compared by the two-sided log-rank test.
p values <0.05 were regarded as significant in all analy-
ses. All analyses were performed using the statistical soft-
ware Statistica 10 (Stat Soft Inc.).
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Results
Immunohistochemistry for GrB+ cells
GrB+ cells were predominantly detected in the tumor 
stroma. They were less abundant within the cancer cell 
nests (Fig. 1a). For further study, the intraepithelial cell 
index was assessed.
The median number of IE GrB+ cells was 3 (range 
0.00–13.33) per single high-power field (HPF). Patients in 
the advanced stage of the disease (35 metastatic cases) and 
in the locally limited stage (41 non-metastatic cases) had 
primary cancer nests that were similarly infiltrated by (IE) 
GrB+ cells (median 3.17 vs. 2.63, p = 0.07).
In 11 cases, no IE GrB+ cells were observed (14.47 %, 
GrB-negative tumors).
GrB-negative tumors exhibited a higher degree of mor-
phological differentiation and were less frequently associ-
ated with lymph node metastases (Table 1).
The median number of GrB+ cells infiltrating lymph 
node metastases was 0.83 (range 0.00–8.33). A lack of 
intracarcinomatous GrB+ cells in nodal metastases was 
observed in 6 of 28 cases (21.43 %), whereas the primary 
tumors from these patients contained IE GrB+ cells. The 
lack of GrB+ cells within metastases does not influence 
overall survival (p = 0.512).
Immunohistochemistry for CD56+ cells
CD56+ T cells were detected within cancer cell nests and 
sporadically in the mesenchymal stroma (Fig. 1b).
The median number of (IE) CD56+ cells was 2 (range 
0.00–37) per single high-power field (HPF). Patients in 
the advanced stage of the disease (35 metastatic cases) 
had primary cancer nests that were more infiltrated 
by (IE) CD56+ cells than patients in the locally lim-
ited stage (41 non-metastatic cases) (median 2 vs. 1.67, 
p = 0.05).
Fig. 1  Microphotograph of immunohistochemical staining for CD56+ cells (a) and GrB+ cells (b) within the primary cancer nest
Table 1  Comparison of clinicopathological features between patients having primary tumors negative and positive for GrB+ as well as CD56+ 
cells
Bold values indicate statistical significance
Clinicopathological feature IE GRB p IE CD56 p
Negative (n = 11) Positive (n = 61) Negative (n = 10) Positive (n = 65)
Age /median/ 62 70 0.134 74 69 0.554
depth of invasion /median/ 6 7.03 0.204 6.63 7 0.291
G1/G2 + G3 8/3 16/45 0.049 4/6 22/43 0.731
G1/G2/G3 8/1/2 16/28/17 0.009 4/3/3 22/26/17 0.832
pT 10/1/0 55/5/1 0.909 8/2/0 60/4/1 0.306
meta+/meta− 2/9 32/29 0.05 5/5 29/36 1.0
FIGO stage I/II/III/IV 8/1/2/0 28/1/28/4 0.130 4/1/4/1 35/1/26/3 0.374
recurrence +/− 1/10 14/47 0.439 2/8 13/52 1.0
Overall survival ns ns
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A lack of IE CD56+ infiltrates was observed in 10 of 
76 cases (13.16 %). This group did not correspond with the 
GrB-negative patients described above.
No differences were observed in all compared clinico-
pathological features between cases with and without (IE) 
CD56+ infiltrates (Table 1).
The median number of CD56+ T cells infiltrating 
lymph node metastases was 1.16 (range 0.00–10). A lack of 
CD56+ infiltrates within nodal metastases was observed in 
8 of 35 cases (22.86 %). Only 2 patients had primary nests 
that were not infiltrated by IE CD56+ cells.
The lack of CD56+ cells in lymph node metastases had 
no impact on overall survival (p = 0.3012).
Correlation of IE CD56+ and IE GrB+ cells 
with clinicopathological features
The number of IE CD56+ (per HPF) was correlated with 
the depth of invasion and recurrence, while the intensity 
of the IE GrB+ lymphocytes was correlated with age and 
tumor grade based on a 2-tier scale: G1 versus G2 + G3 
(Table 2).
Prognostic significance of IE GrB+ cells at the primary 
site
Patients were divided into GrB low- and high-intensity 
groups (low GrB+ and high GrB +, respectively) based on 
the median value of IE GrB+ cells.
With the exception of age (high GrB+ patients were 
older than low GrB+ patients), no differences were 
observed between groups in the pathological features ana-
lyzed here (Table 3).
While no differences in overall survival (OS) were 
observed between high GrB+ and low GrB+ cases in 
the general cohort (Fig. 2a) (F Cox p = 0.479), more IE 
GrB+ cells than the median were correlated with longer 
OS among cases with local disease (F Cox p = 0.028) 
(Fig. 2b).
Prognostic significance of IE CD56+ cells at the primary 
site
Patients were divided into CD56 low- and high-intensity 
groups (low CD56+ and high CD56+, respectively) based 
on the median value of IE CD56+ cells.
No differences were observed in all analyzed clinico-
pathological features among different CD56 infiltration cat-
egories in our cohort (Table 3).
While no differences in overall survival were observed 
between these groups in the general cohort (F Cox 
p = 0.141) (Fig. 2c), intensities of IE CD56+ cells exceed-
ing the median (high-CD56+) were correlated with longer 
OS among patients with metastatic dissemination (F Cox 
p = 0.009) (Fig. 2d).
Discussion
The distribution of CD56+ cells and GrB expressing cells 
at the primary site differed in the vSCC cases analyzed 
Table 2  Correlation of IE CD56+ and IE GrB+ infiltrates with clin-
icopathological features of vSCC patients
Bold values indicate statistical significance
Clinicopathological feature IE CD56+ p IE GzB+ p
Age r = −0.126 0.280 r = 0.333 0.004
pT r = 0.001 0.992 r = 0.021 0.862
depth of invasion r = 0.339 0.003 r = 0.196 0.102
G1/G2/G3 r = 0.023 0.849 r = 0.207 0.080
G1/G2 + G3 r = 0.093 0.432 r = 0.304 0.009
pN r = 0.222 0.057 0.216 0.069
FIGO stage I/II/III/IV r = 0.208 0.075 r = 0.226 0.056
recurrence +/− r = −0.295 0.011 r = 0.109 0.362
Table 3  Differences in clinicopathological features between patients having primary tumors infiltrated with low and high numbers of intraepi-
thelial GrB+ and CD56+ cells (median as a cutoff point)
Bold values indicate statistical significance
Clinicopathological feature Low (IE)GrB+ High (IE)GRB+ p Low (IE)CD56+ High (IE)CD56+ p
Age /median/ 65 71 0.011 69 69 0.996
depth of invasion /median/ 7 7.4 0.355 6.25 7.75 0.01
G1/G2/G3 15/9/8 9/20/11 0.070 17/15/13 9/14/7 0.509
G1/G2 + G3 15/17 9/31 0.044 17/28 9/21 0.622
pT 30/1/1 35/5/0 0.202 41/3/1 27/3/0 0.632
meta+/meta− 12/20 22/18 0.161 17/28 17/13 0.155
FIGO stage I/II/III/IV 19/1/11/1 17/1/19/3 0.496 27/1/15/2 12/1/15/2 0.410
recurrence +/− 5/27 10/30 0.392 5/40 10/20 0.036
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here. CD56+ cells were mostly detected within the can-
cer nests, while the GrB+ cells were predominant in the 
tumor stroma. Only activated cytotoxic lymphocytes and 
NK/NKT cells are able to express granzyme B [12, 13]. 
The higher stromal distribution of GrB+ cells suggests that 
the vast majority of immune effectors are activated outside 
the cancer nests, chiefly through mechanisms unrelated to 
the recognition of vSCC antigens.
Moreover, the large discrepancy between IE GrB + infil-
trates (median 3) and the cumulative number of intraepithe-
lial immune effectors (median 2 for IE CD56+ and median 
19 for IE CD8+ infiltrates) recently described by our group 
for this cohort [14] could suggest that the cytolytic power 
of the immune system has been lost outside rather than 
inside cancer nests.
This could explain the lack of prognostic significance of 
CD8+ lymphocytes in vSCC [15, 16] and suggests that the 
number of TILs present in the stroma probably provides a 
better indication of coexisting inflammatory processes than 
the immunogenicity of cancer cells.
In contrast, TILs within cancer nests are certainly con-
nected with direct spontaneous immune reactions against 
cancer [20, 21], and therefore, only these intraepithelial 
infiltrates (IE) were analyzed further.
We found that the median numbers of IE GrB+ and IE 
CD56+ cells were comparable (3 and 2 per HPF within 
the primary cancer nest and 0.83 and 1.016 per HPF within 
lymph node metastases, respectively). This could suggest 
that these cells are the same cells, but considering the cur-
rent results together with our previous data on IE CD8+ 
Fig. 2  Kaplan–Meier survival curves for overall survival of patients. 
a low CD56+/high CD56+ infiltrates within cancer nests in the gen-
eral population. b low CD56+/high CD56+ infiltrates within cancer 
nests in metastatic cases. c low GrB+/high GrB+ infiltrates within 
cancer nests in the general population. d low GrB+/high GrB+ infil-
trates within cancer nests in non-metastatic cases
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T lymphocytes in this cohort [14], we believe that only a 
small subset of IE CD56+ cells could be granzyme B 
positive.
This is supported by further results indicating that IE 
CD56+ and IE GrB+ infiltrates have separate correlations 
with clinico-pathological features in patients with vSCC.
The intensity of IE CD56+ cells was significantly cor-
related with depth of invasion and recurrence, while the 
intensity of IE GrB+ lymphocytes was correlated with age 
and tumor grade.
Patients in the advanced stage of the disease had pri-
mary cancer nests that were more infiltrated by IE CD56+ 
cells than cases in the locally limited stage. This was not 
observed for IE GrB+ infiltrates. These data could suggest 
that IE CD56+ infiltrates coincide with more aggressive 
tumors.
However, neither high IE CD56+ nor high IE GrB+ 
infiltrates had an impact on overall survival in vSCC 
patients. Further, to analyze the prognostic significance 
of these cells, we decided to subdivide the cohort into 2 
groups: non-metastatic and metastatic. From the immuno-
logical point of view, patients with local and disseminated 
disease represent unsuccessful and successful immune 
escape, respectively [22]. Therefore, subdividing the gen-
eral cohort into these two subtypes and conducting separate 
survival analyses seems to be justified.
High IE GrB+ infiltrates were correlated with longer OS 
in non-metastatic cases. It is unclear whether the immune 
surveillance performed by the cytotoxic function of the 
activated effectors of adaptive (CD8+ T cells) and innate 
(NK/NKT cells) immunity is efficient until tumors develop 
mechanisms of immune escape. Various proportions of the 
adaptive and innate effectors could be involved in gran-
zyme B-dependent cytotoxicity because of the diverse 
expression of MHC antigens, costimulatory molecules and 
antigen-presenting cell (APC) statuses in different cancers, 
as well as the different number of regulatory cells within 
tumor tissue [23]. This could explain why the effectors of 
adaptive (CD8+) immunity did not reveal prognostic sig-
nificance when analyzed separately [14].
Natural killer cells are considered to play a major role in 
the early stages of tumor development [11, 24, 25]. Previ-
ous reports showed that while innate immunity represents 
the first line of pathogen defense [26], most human tumor 
cells are resistant to perforin-mediated NK cell lysis, and 
NK cells are rarely found among TILs in advanced cancer 
cases [11].
Interestingly, the correlation between the intensity of IE 
CD56+ (NK/NKT) cells and survival was observed among 
metastatic vSCC patients, while the prognostic signifi-
cance of granzyme B-dependent killing was not observed 
in this subgroup. Either these immune cells defending 
against metastases have already released GrB and are now 
GrB(−), or they represent a distinct subset of NK/NKT 
cells mediating tumor destruction by mechanisms other 
than GrB-mediated cytotoxicity. The second concept is 
consistent with more recent data suggesting that the pri-
mary biological role of NKs might not be the elimination 
of tumor targets, but rather the facilitation of dendritic-cell 
(DC)–T-cell interactions. As a consequence, this process 
may drive the immune responses against tumor-associated 
antigens (TAAs) [27]. This hypothesis could be supported 
by the fact that a diminished infiltration of CD4+ T cells 
is observed among advanced vSCC cases (authors’ unpub-
lished data). CD4+ T-cell-deficient intratumoral infiltrates 
may impair the adaptive immune response, which is pri-
marily regulated by DCs.
Recent data suggest that in addition to granzyme-medi-
ated lysis, NK/NKT cells constitutively express several 
ligands of the TNF-family and can induce apoptosis in a 
broad variety of tumor-cell targets [28]. This mechanism 
might be of greater biological importance than secretory, 
granule-mediated killing, largely because of the expression 
of TNF-family ligands by tumor cells resulting in their sen-
sitivity to apoptotic death [29].
Interestingly, patients with disseminated cancer were 
significantly older than patients without metastases in the 
cohort analyzed here [15]. It is known that immune anti-
tumor responses can be influenced by the gradual deterio-
ration of the immune system with age [10]. A significant 
expansion in the number of NK cells was observed upon 
aging [30], but some controversy remains concerning 
the efficacy of their cytotoxic function, which has been 
described as comparable to [31] or decreased [32, 33] com-
pared with younger individuals.
Conclusion
IE GrB+ infiltrates, which indicate the cytolytic power 
of combined adaptive and innate immune effectors, and 
IE CD56+ infiltrates, which indicate NK/NKT cells of 
unknown functional status, correlate with longer OS among 
non-metastatic and metastatic vSCC cases, respectively.
Both of these significant results suggest that immuno-
logical effects contribute to improved clinical outcomes in 
vSCC.
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